Chemical Structure (Bortezomib 01)
Chemical structure of bortezomib, an active ingredient in injection, powder, lyophilized for solution dosage form.*
Bortezomib Injection, Powder, Lyophilized, For Solution
Product Images NDC 0409-1704
10 FDA label images from Hospira, Inc. · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Bortezomib (NDC 0409-1704). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Bortezomib 02)
A survival curve comparing the percentage of patients over time (months) between two treatment groups, B-MP and MP, with B-MP showing higher survival rates. The x-axis represents time in months, and the y-axis shows the percentage of patients. Patient numbers at risk at various time points and a p-value are included below the graph.*
Figure 2 (Bortezomib 03)
A Kaplan-Meier survival curve comparing the percentage of patients over time (months) between two treatments labeled B-MP and MP. The vertical axis shows the percentage of patients, and the horizontal axis shows time in months up to 78 months. Patient counts at risk are listed below the time axis for both groups, with a p-value from a log-rank test indicated as less than 0.05.*
Figure 3 (Bortezomib 04)
A Kaplan-Meier survival curve comparing the proportion of patients over time (days) for Bortezomib and Dexamethasone treatment groups. The graph shows higher patient survival proportion with Bortezomib versus Dexamethasone over approximately 450 days, with a p-value less than 0.0001 indicating statistical significance. Patient counts at various time points are included below the x-axis.*
Figure 4 (Bortezomib 05)
A survival curve chart comparing the proportion of patients over time (days) for Bortezomib versus Dexamethasone treatment groups. The Bortezomib group is marked with blue circles, and the Dexamethasone group with red crosses. Time points indicate the number of patients remaining in each group, with a p-value less than 0.05 from a log-rank test noted.*
Logo (Bortezomib 06)
Principal Display Panel (2.5 mg Vial Label)
Label for Bortezomib Injection 2.5 mg/vial, a lyophilized powder for intravenous or subcutaneous use. The single-dose vial cautions to discard unused portions and highlights it as a hazardous agent. Storage instructions and manufacturer details for Hospira, Inc. and Gland Pharma Limited are also visible.*
Principal Display Panel (2.5 mg Vial Carton)
Packaging label for Bortezomib for Injection 2.5 mg/vial, a single-dose vial powder for injection, lyophilized, for intravenous or subcutaneous use. The label includes reconstitution information detailing volumes of sodium chloride injection for different administration routes. The manufacturer is Hospira, Inc. The label also contains caution about hazardous agent handling and storage instructions.*
Principal Display Panel (1 mg Vial Label)
Label for Bortezomib Injection 1 mg per vial, lyophilized powder for solution, single-dose vial. Suitable for intravenous or subcutaneous use. The label includes the NDC number 0409-1704-01, caution note as hazardous agent, and is manufactured by Gland Pharma Limited for Hospira, Inc.*
Principal Display Panel (1 mg Vial Carton)
Packaging label for Bortezomib for Injection 1 mg/vial, single-dose lyophilized powder for injection by Hospira, Inc. The label indicates use for intravenous or subcutaneous administration, includes reconstitution instructions with sodium chloride for both injection routes, and cautions that the product is a hazardous agent. It is manufactured by Gland Pharma Limited in India for Hospira, USA.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
